Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease

Jun Miyoshi, Tadakazu Hisamatsu, Katsuyoshi Matsuoka, Makoto Naganuma, Yuriko Maruyama, Kazuaki Yoneno, Kiyoto Mori, Hiroki Kiyohara, Kosaku Nanki, Susumu Okamoto, Tomoharu Yajima, Yasushi Iwao, Haruhiko Ogata, Toshifumi Hibi, Takanori Kanai

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: We evaluated the clinical efficacy of adalimumab (ADA) for Crohn's disease (CD) and analyzed predictive factors for clinical remission and long-term prognosis. Methods: We retrospectively reviewed the medical records of 45 patients treated with ADA for CD at Keio University Hospital between October 2010 and March 2014. Clinical remission was defined as a Harvey-Bradshaw index of ≤ 4. Results: Twenty-eight of 45 patients (62.2%) achieved clinical remission at week 4. Among these 28 patients, 18 patients (64.3%) maintained clinical remission at week 26, and among these, 16 patients (88.9%) maintained clinical remission at week 52. Absence of a history of bowel resection and absence of prior anti-tumor necrosis factor (anti-TNF) therapy were significant predictive factors for clinical remission at week 4 upon multivariate logistic regression analyses. Younger age and a disease duration of ≤ 3 years correlated with clinical remission at week 26 upon univariate analyses. Patients without a history of bowel resection showed significantly better long-term prognosis than those with a history of bowel resection (p = 0.01). None of the patients contracted a serious infectious disease. Conclusions: Younger age, shorter duration of disease, being naive to anti-TNF antagonists, and absence of a history of bowel resection were associated with the efficacy of ADA in CD patients.

Original languageEnglish
Pages (from-to)130-136
Number of pages7
JournalDigestion
Volume90
Issue number2
DOIs
Publication statusPublished - 2014 Nov 7

Fingerprint

Crohn Disease
Tumor Necrosis Factor-alpha
Adalimumab
Medical Records
Communicable Diseases
Logistic Models
Regression Analysis

Keywords

  • Adalimumab
  • Anti-tumor necrosis factor antagonist
  • Bowel resection
  • Clinical remission
  • Crohn's disease

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease. / Miyoshi, Jun; Hisamatsu, Tadakazu; Matsuoka, Katsuyoshi; Naganuma, Makoto; Maruyama, Yuriko; Yoneno, Kazuaki; Mori, Kiyoto; Kiyohara, Hiroki; Nanki, Kosaku; Okamoto, Susumu; Yajima, Tomoharu; Iwao, Yasushi; Ogata, Haruhiko; Hibi, Toshifumi; Kanai, Takanori.

In: Digestion, Vol. 90, No. 2, 07.11.2014, p. 130-136.

Research output: Contribution to journalArticle

Miyoshi, J, Hisamatsu, T, Matsuoka, K, Naganuma, M, Maruyama, Y, Yoneno, K, Mori, K, Kiyohara, H, Nanki, K, Okamoto, S, Yajima, T, Iwao, Y, Ogata, H, Hibi, T & Kanai, T 2014, 'Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease', Digestion, vol. 90, no. 2, pp. 130-136. https://doi.org/10.1159/000365783
Miyoshi, Jun ; Hisamatsu, Tadakazu ; Matsuoka, Katsuyoshi ; Naganuma, Makoto ; Maruyama, Yuriko ; Yoneno, Kazuaki ; Mori, Kiyoto ; Kiyohara, Hiroki ; Nanki, Kosaku ; Okamoto, Susumu ; Yajima, Tomoharu ; Iwao, Yasushi ; Ogata, Haruhiko ; Hibi, Toshifumi ; Kanai, Takanori. / Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease. In: Digestion. 2014 ; Vol. 90, No. 2. pp. 130-136.
@article{15a324a6342149f183e57c8f857d75e2,
title = "Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease",
abstract = "Background: We evaluated the clinical efficacy of adalimumab (ADA) for Crohn's disease (CD) and analyzed predictive factors for clinical remission and long-term prognosis. Methods: We retrospectively reviewed the medical records of 45 patients treated with ADA for CD at Keio University Hospital between October 2010 and March 2014. Clinical remission was defined as a Harvey-Bradshaw index of ≤ 4. Results: Twenty-eight of 45 patients (62.2{\%}) achieved clinical remission at week 4. Among these 28 patients, 18 patients (64.3{\%}) maintained clinical remission at week 26, and among these, 16 patients (88.9{\%}) maintained clinical remission at week 52. Absence of a history of bowel resection and absence of prior anti-tumor necrosis factor (anti-TNF) therapy were significant predictive factors for clinical remission at week 4 upon multivariate logistic regression analyses. Younger age and a disease duration of ≤ 3 years correlated with clinical remission at week 26 upon univariate analyses. Patients without a history of bowel resection showed significantly better long-term prognosis than those with a history of bowel resection (p = 0.01). None of the patients contracted a serious infectious disease. Conclusions: Younger age, shorter duration of disease, being naive to anti-TNF antagonists, and absence of a history of bowel resection were associated with the efficacy of ADA in CD patients.",
keywords = "Adalimumab, Anti-tumor necrosis factor antagonist, Bowel resection, Clinical remission, Crohn's disease",
author = "Jun Miyoshi and Tadakazu Hisamatsu and Katsuyoshi Matsuoka and Makoto Naganuma and Yuriko Maruyama and Kazuaki Yoneno and Kiyoto Mori and Hiroki Kiyohara and Kosaku Nanki and Susumu Okamoto and Tomoharu Yajima and Yasushi Iwao and Haruhiko Ogata and Toshifumi Hibi and Takanori Kanai",
year = "2014",
month = "11",
day = "7",
doi = "10.1159/000365783",
language = "English",
volume = "90",
pages = "130--136",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease

AU - Miyoshi, Jun

AU - Hisamatsu, Tadakazu

AU - Matsuoka, Katsuyoshi

AU - Naganuma, Makoto

AU - Maruyama, Yuriko

AU - Yoneno, Kazuaki

AU - Mori, Kiyoto

AU - Kiyohara, Hiroki

AU - Nanki, Kosaku

AU - Okamoto, Susumu

AU - Yajima, Tomoharu

AU - Iwao, Yasushi

AU - Ogata, Haruhiko

AU - Hibi, Toshifumi

AU - Kanai, Takanori

PY - 2014/11/7

Y1 - 2014/11/7

N2 - Background: We evaluated the clinical efficacy of adalimumab (ADA) for Crohn's disease (CD) and analyzed predictive factors for clinical remission and long-term prognosis. Methods: We retrospectively reviewed the medical records of 45 patients treated with ADA for CD at Keio University Hospital between October 2010 and March 2014. Clinical remission was defined as a Harvey-Bradshaw index of ≤ 4. Results: Twenty-eight of 45 patients (62.2%) achieved clinical remission at week 4. Among these 28 patients, 18 patients (64.3%) maintained clinical remission at week 26, and among these, 16 patients (88.9%) maintained clinical remission at week 52. Absence of a history of bowel resection and absence of prior anti-tumor necrosis factor (anti-TNF) therapy were significant predictive factors for clinical remission at week 4 upon multivariate logistic regression analyses. Younger age and a disease duration of ≤ 3 years correlated with clinical remission at week 26 upon univariate analyses. Patients without a history of bowel resection showed significantly better long-term prognosis than those with a history of bowel resection (p = 0.01). None of the patients contracted a serious infectious disease. Conclusions: Younger age, shorter duration of disease, being naive to anti-TNF antagonists, and absence of a history of bowel resection were associated with the efficacy of ADA in CD patients.

AB - Background: We evaluated the clinical efficacy of adalimumab (ADA) for Crohn's disease (CD) and analyzed predictive factors for clinical remission and long-term prognosis. Methods: We retrospectively reviewed the medical records of 45 patients treated with ADA for CD at Keio University Hospital between October 2010 and March 2014. Clinical remission was defined as a Harvey-Bradshaw index of ≤ 4. Results: Twenty-eight of 45 patients (62.2%) achieved clinical remission at week 4. Among these 28 patients, 18 patients (64.3%) maintained clinical remission at week 26, and among these, 16 patients (88.9%) maintained clinical remission at week 52. Absence of a history of bowel resection and absence of prior anti-tumor necrosis factor (anti-TNF) therapy were significant predictive factors for clinical remission at week 4 upon multivariate logistic regression analyses. Younger age and a disease duration of ≤ 3 years correlated with clinical remission at week 26 upon univariate analyses. Patients without a history of bowel resection showed significantly better long-term prognosis than those with a history of bowel resection (p = 0.01). None of the patients contracted a serious infectious disease. Conclusions: Younger age, shorter duration of disease, being naive to anti-TNF antagonists, and absence of a history of bowel resection were associated with the efficacy of ADA in CD patients.

KW - Adalimumab

KW - Anti-tumor necrosis factor antagonist

KW - Bowel resection

KW - Clinical remission

KW - Crohn's disease

UR - http://www.scopus.com/inward/record.url?scp=84908590628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908590628&partnerID=8YFLogxK

U2 - 10.1159/000365783

DO - 10.1159/000365783

M3 - Article

VL - 90

SP - 130

EP - 136

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 2

ER -